Back to Search Start Over

Therapeutic Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Recovering From Murine Pulmonary Emphysema Under Cigarette Smoke Exposure.

Authors :
Chen XY
Chen YY
Lin W
Chen CH
Wen YC
Hsiao TC
Chou HC
Chung KF
Chuang HC
Source :
Frontiers in medicine [Front Med (Lausanne)] 2021 Sep 27; Vol. 8, pp. 713824. Date of Electronic Publication: 2021 Sep 27 (Print Publication: 2021).
Publication Year :
2021

Abstract

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) were shown to have potential for immunoregulation and tissue repair. The objective of this study was to investigate the effects of hUC-MSCs on emphysema in chronic obstructive pulmonary disease (COPD). The C57BL/6JNarl mice were exposed to cigarette smoke (CS) for 4 months followed by administration of hUC-MSCs at 3 × 10 <superscript>6</superscript> (low dose), 1 × 10 <superscript>7</superscript> (medium dose), and 3 × 10 <superscript>7</superscript> cells/kg body weight (high dose). The hUC-MSCs caused significant decreases in emphysema severity by measuring the mean linear intercept (MLI) and destructive index (DI). A decrease in neutrophils (%) and an increase in lymphocytes (%) in bronchoalveolar lavage fluid (BALF) were observed in emphysematous mice after hUC-MSC treatment. Lung levels of interleukin (IL)-1β, C-X-C motif chemokine ligand 1 (CXCL1)/keratinocyte chemoattractant (KC), and matrix metalloproteinase (MMP)-12 significantly decreased after hUC-MSC administration. Significant reductions in tumor necrosis factor (TNF)-α, IL-1β, and IL-17A in serum occurred after hUC-MSC administration. Notably, the cell viability of lung fibroblasts improved with hUC-MSCs after being treated with CS extract (CSE). Furthermore, the hUC-MSCs-conditioned medium (hUC-MSCs-CM) restored the contractile force, and increased messenger RNA expressions of elastin and fibronectin by lung fibroblasts. In conclusion, hUC-MSCs reduced inflammatory responses and emphysema severity in CS-induced emphysematous mice.<br />Competing Interests: WL, C-HC, and Y-CW are employed by Meridigen Biotech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Chen, Chen, Lin, Chen, Wen, Hsiao, Chou, Chung and Chuang.)

Details

Language :
English
ISSN :
2296-858X
Volume :
8
Database :
MEDLINE
Journal :
Frontiers in medicine
Publication Type :
Academic Journal
Accession number :
34646841
Full Text :
https://doi.org/10.3389/fmed.2021.713824